NCT05509569View on ClinicalTrials.gov

A Survey of Icatibant in Pediatric Participants with Hereditary Angioedema

Active, not recruitingOBSERVATIONAL
Enrollment

32

Participants

Timeline

Start Date

August 24, 2022

Primary Completion Date

October 31, 2025

Study Completion Date

October 31, 2025

Conditions
Hereditary Angioedema (HAE)
Interventions
DRUG

Icatibant

Icatibant, 10 to 30 mg, Subcutaneous injection

Trial Locations (1)

Unknown

Takeda selected site, Tokyo

Sponsors

Lead Sponsor

Takeda
All Listed Sponsors
lead

Takeda

INDUSTRY

NCT05509569 - A Survey of Icatibant in Pediatric Participants with Hereditary Angioedema | Biotech Hunter | Biotech Hunter